| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Not applicable; Tetrahydro-11-deoxycortisol is an endogenous metabolite and biomarker rather than a pharmacologically active drug. It is involved in the steroidogenesis pathway as a downstream metabolite of 11-deoxycortisol. Deficiencies in 11beta-hydroxylase (CYP11B1) or 21-hydroxylase lead to elevated levels of this compound in urine, making it a diagnostic marker for these enzyme deficiencies. The compound itself does not have a defined "drug target" but is used to study adrenal steroid metabolism and to diagnose inborn errors of steroidogenesis.
|
|---|---|
| ln Vitro |
Endogenous metabolites are those that the Kyoto Encyclopedia of Genes and Genomes has identified as products or substrates of the approximately 1900 metabolic enzymes that are encoded in human genome. Numerous of these metabolites have been shown to have harmful effects, as evidenced by the body of literature [1].
Tetrahydro-11-deoxycortisol does not exert direct pharmacological effects in vitro; it is an endogenous urinary steroid metabolite used as a biomarker. In cell-free systems, it can be quantified by LC-MS/MS or immunoassay for diagnostic purposes. It is not typically tested for biological activity in cell-free enzyme assays because it is a terminal metabolite rather than an active signaling molecule. As an endogenous compound present in urine, it is measured to assess adrenal function and to diagnose disorders such as 11beta-hydroxylase deficiency. It may also be used as a reference standard in analytical chemistry for steroid profiling in urine samples. |
| ln Vivo |
Tetrahydro-11-deoxycortisol is an endogenous urinary metabolite whose levels in vivo are used as a biomarker for adrenal disorders. Elevated urinary excretion of THS is observed in patients with 11beta-hydroxylase deficiency, adrenocortical carcinoma (ACC), and adrenocortical adenoma (ACA), with higher levels in ACC compared to ACA. It is also involved in the assessment of adrenal gland function and congenital adrenal hyperplasia. While it is not a therapeutic agent, its quantification in urine helps diagnose these conditions and monitor disease progression. It is often analyzed by mass spectrometry in clinical research settings.
|
| Enzyme Assay |
For the detection and quantification of Tetrahydro-11-deoxycortisol in urine, a common method is liquid chromatography-tandem mass spectrometry (LC-MS/MS) with isotope dilution. Collect urine samples (e.g., 24-hour urine collection). Add deuterated internal standard (e.g., Tetrahydro-11-deoxycortisol-d4). Perform solid-phase extraction (SPE) to purify and concentrate steroids from the urine matrix. Separate the extract on a C18 reverse-phase column using a mobile phase gradient of water and methanol (or acetonitrile) containing 0.1% formic acid or ammonium fluoride. Detect using negative ion electrospray ionization (ESI-) and multiple reaction monitoring (MRM). Typical transitions: Tetrahydro-11-deoxycortisol m/z 349 → 313, 349 → 269. Quantify by isotope dilution against a calibration curve.
|
| Cell Assay |
For cell-based studies, Tetrahydro-11-deoxycortisol is not typically used in live cell assays because it is a urinary metabolite rather than a bioactive signaling molecule. However, for studies investigating steroid metabolism, adrenal cells (e.g., H295R adrenocortical carcinoma cells) can be cultured and treated with precursors such as 11-deoxycortisol. Tetrahydro-11-deoxycortisol can be measured in the culture medium by LC-MS/MS after extraction as described above. This allows researchers to study the activity of steroidogenic enzymes such as 11beta-hydroxylase and 21-hydroxylase in vitro. Add deuterated internal standard to cell culture supernatants, perform SPE, and analyze by LC-MS/MS to quantify THS levels. This method is used to evaluate the effects of drugs or genetic modifications on steroidogenesis.
|
| Animal Protocol |
For in vivo studies, Tetrahydro-11-deoxycortisol is measured as a urinary biomarker rather than administered as a test compound. In animal models (e.g., rats) of adrenal disorders, collect urine samples (often 24-hour urine collections) at baseline and after treatments. Add deuterated internal standard to urine samples. Perform solid-phase extraction (SPE) to purify steroids. Analyze by LC-MS/MS as described in the assay protocol above. Quantify THS levels to assess adrenal function, enzyme deficiencies, or the effects of drug treatments on steroid metabolism. Urinary THS levels are elevated in conditions of 11beta-hydroxylase deficiency. This method is used for preclinical biomarker studies and for evaluating the efficacy of drugs targeting steroidogenic enzymes.
|
| ADME/Pharmacokinetics |
Tetrahydro-11-deoxycortisol: Molecular formula C21H34O4. Molecular weight: 350.49 g/mol. Appearance: White to off-white solid. Melting point: 168-172degC. Solubility: DMF 30 mg/mL, DMSO 30 mg/mL, Ethanol 30 mg/mL, Ethanol:PBS(pH 7.2) (1:1) 0.2 mg/mL. Purity: ≥95%. Storage: Store powder at -20degC, protected from light and moisture. It is a controlled substance for research use. Shipping: Room temperature in continental US; may vary elsewhere. It is also known as NSC 53901, 5beta-Pregnane-3alpha,17alpha,21-triol-20-one, and THS.
|
| Toxicity/Toxicokinetics |
Tetrahydro-11-deoxycortisol has low toxicity as an endogenous metabolite at physiological levels. It is not intended for human therapeutic use and is only supplied as a research reference standard for analytical and diagnostic applications. Standard laboratory precautions should be followed when handling the pure compound: wear appropriate personal protective equipment (lab coat, gloves, safety glasses), avoid inhalation and contact with skin/eyes, and wash hands thoroughly after handling. It is a steroid compound and should be handled with care to avoid contamination. Always consult the Safety Data Sheet (SDS) for detailed safety information. Not for clinical use.
|
| References | |
| Additional Infomation |
3α,17α,21-Trihydroxy-5β-pregnane-20-one is a 21-hydroxy steroid.
Tetrahydro-11-deoxycortisol (THS) is the primary urinary metabolite of 11-deoxycortisol and a valuable biomarker for 11beta-hydroxylase deficiency, a condition resulting from mutations in CYP11B1. Urinary levels of THS are also elevated in patients with adrenocortical carcinoma (ACC) and adrenocortical adenoma (ACA) but are higher in ACC, making it a useful diagnostic tool for distinguishing between these adrenal tumors. The compound is supplied as a research reference standard for studies of steroid metabolism, steroidogenesis, and adrenal disorders. It is used in clinical research to study metabolic pathways of corticosteroids and the effects of enzyme deficiencies in adrenal steroid metabolism, particularly involving 11beta-hydroxylase and 21-hydroxylase. For research use only, not for therapeutic use. |
| Molecular Formula |
C21H34O4
|
|---|---|
| Molecular Weight |
350.49
|
| Exact Mass |
350.246
|
| CAS # |
68-60-0
|
| PubChem CID |
65555
|
| Appearance |
White to off-white solid powder
|
| Density |
1.186g/cm3
|
| Boiling Point |
505.1ºC at 760 mmHg
|
| Flash Point |
273.4ºC
|
| Index of Refraction |
1.56
|
| LogP |
2.682
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
562
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
|
| InChi Key |
UPTAPIKFKZGAGM-FAIYVORSSA-N
|
| InChi Code |
InChI=1S/C21H34O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h13-17,22-23,25H,3-12H2,1-2H3/t13-,14-,15-,16+,17+,19+,20+,21+/m1/s1
|
| Chemical Name |
1-[(3R,5R,8R,9S,10S,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-hydroxyethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8531 mL | 14.2657 mL | 28.5315 mL | |
| 5 mM | 0.5706 mL | 2.8531 mL | 5.7063 mL | |
| 10 mM | 0.2853 mL | 1.4266 mL | 2.8531 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
